On September 11, 2021, Treatment Action Group’s Joelle Dountio Ofinboudem presented new data on the registration of the hepatitis C cure at the Conference on Liver Disease in Africa (COLDA) 2021. The presentation titled, “Have a Heart, Save My Liver! Who Has Access to the Cure in Africa,” explains that accelerating treatment uptake across Africa is urgently needed to meet WHO hepatitis C targets by 2030. This can be achieved by supporting and funding community engagement efforts; optimizing the WHO Collaborative Registration Procedure to circumvent national registration hurdles; pooling procurement for diagnostics and treatments; and committing to data transparency and access.

Data were collected and analyzed from the free public mapCrowd platform from November 19, 2020 to April 30, 2021, and were provide by in-country contributors and partner organizations. Data focused on seven pangenotypic DAA regimens most commonly prescribed in countries: originator and generic sofosbuvir and daclatasvir, sofosbuvir/velpatasvir, sofosbuvir/ledipasvir, G/P, and fixed-dose combinations (FDC) of sofosbuvir/daclatasvir.